Several targeted therapies have been developed to inhibit the activity of EGFR in cancer cells. These include tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and osimertinib, which block the kinase activity of EGFR, preventing its signaling. Monoclonal antibodies like cetuximab and panitumumab can also target EGFR by binding to its extracellular domain, blocking ligand binding and receptor activation. These treatments are particularly effective in cancers with specific EGFR mutations.
